These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
242 related items for PubMed ID: 32720495
1. Prognosis and Risk Factors of Coronary Artery Lesions before Immunoglobulin Therapy in Children with Kawasaki Disease. Qiu H, Jia C, Wang Z, He Y, Rong X, Wu R, Chu M, Shi H. Balkan Med J; 2020 Oct 23; 37(6):324-329. PubMed ID: 32720495 [Abstract] [Full Text] [Related]
2. Factors affecting the duration of coronary artery lesions in patients with the Kawasaki disease: a retrospective cohort study. Zhang X, He Y, Shao Y, Hang B, Xu Z, Chu M. Pediatr Rheumatol Online J; 2021 Jun 26; 19(1):96. PubMed ID: 34174872 [Abstract] [Full Text] [Related]
3. Facial nerve palsy may indicate coronary artery lesions in Kawasaki disease. Chen J, Liu P, Hu W, Xu Y, Deng J. Clin Rheumatol; 2021 Oct 26; 40(10):4191-4197. PubMed ID: 34059986 [Abstract] [Full Text] [Related]
4. Clinical characteristics of Kawasaki syndrome and the risk factors for coronary artery lesions in China. Ruan Y, Ye B, Zhao X. Pediatr Infect Dis J; 2013 Oct 26; 32(10):e397-402. PubMed ID: 23722531 [Abstract] [Full Text] [Related]
5. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease. Bal AK, Prasad D, Umali Pamintuan MA, Mammen-Prasad E, Petrova A. Pediatr Neonatol; 2014 Oct 26; 55(5):387-92. PubMed ID: 24636168 [Abstract] [Full Text] [Related]
6. Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease. Honkanen VE, McCrindle BW, Laxer RM, Feldman BM, Schneider R, Silverman ED. Pediatr Cardiol; 2003 Oct 26; 24(2):122-6. PubMed ID: 12457252 [Abstract] [Full Text] [Related]
7. Long-term follow-up of coronary artery lesions in children in Kawasaki syndrome. Maccora I, Calabri GB, Favilli S, Brambilla A, Trapani S, Marrani E, Simonini G. Eur J Pediatr; 2021 Jan 26; 180(1):271-275. PubMed ID: 32556506 [Abstract] [Full Text] [Related]
8. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status. Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H. Postgrad Med; 2018 May 26; 130(4):442-447. PubMed ID: 29745742 [Abstract] [Full Text] [Related]
9. Risk factors for coronary artery lesions in children with Kawasaki disease. Duan J, Jiang H, Lu M. Arch Argent Pediatr; 2020 Oct 26; 118(5):327-331. PubMed ID: 32924395 [Abstract] [Full Text] [Related]
10. Predictive value of red blood cell distribution width for coronary artery lesions in patients with Kawasaki disease. Xu H, Fu S, Wang W, Zhang Q, Hu J, Gao L, Zhu W, Gong F. Cardiol Young; 2016 Aug 26; 26(6):1151-7. PubMed ID: 26435202 [Abstract] [Full Text] [Related]
11. Biomarkers of intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease. Kong WX, Ma FY, Fu SL, Wang W, Xie CH, Zhang YY, Gong FQ. World J Pediatr; 2019 Apr 26; 15(2):168-175. PubMed ID: 30809758 [Abstract] [Full Text] [Related]
12. [Risk factors for coronary artery lesions in children with Kawasaki disease]. Li Y, Wang XM, Liu YL, Shi K, Yang YF, Guo YH. Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec 26; 14(12):938-41. PubMed ID: 23234782 [Abstract] [Full Text] [Related]
13. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease. Berdej-Szczot E, Małecka-Tendera E, Gawlik T, Firek-Pędras M, Szydłowski L, Gawlik A. Kardiol Pol; 2017 Dec 26; 75(3):261-266. PubMed ID: 27995598 [Abstract] [Full Text] [Related]
14. A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease. Yang X, Liu G, Huang Y, Chen S, Du J, Jin H. Cardiol Young; 2015 Aug 26; 25(6):1182-90. PubMed ID: 25597708 [Abstract] [Full Text] [Related]
15. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. Tse SM, Silverman ED, McCrindle BW, Yeung RS. J Pediatr; 2002 Apr 26; 140(4):450-5. PubMed ID: 12006960 [Abstract] [Full Text] [Related]
16. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC. Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997 [Abstract] [Full Text] [Related]
17. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms. Yılmazer MM, Özdemir R, Meşe T, Küçük M, Öner T, Devrim İ, Bayram N, Güven B, Tavlı V. Turk J Pediatr; 2019 May 17; 61(5):648-656. PubMed ID: 32104995 [Abstract] [Full Text] [Related]
18. Risk factors and scores for prediction of coronary artery aneurysms in Kawasaki disease: a European monocentric study. La Vecchia A, Stracquadaino R, Mauri L, Baselli LA, Abdallah R, Cucchetti M, Colli AM, Agostoni C, Dellepiane RM. BMC Pediatr; 2024 Feb 23; 24(1):139. PubMed ID: 38395821 [Abstract] [Full Text] [Related]
19. N-terminal pro-brain natriuretic peptide in acute Kawasaki disease correlates with coronary artery involvement. Adjagba PM, Desjardins L, Fournier A, Spigelblatt L, Montigny M, Dahdah N. Cardiol Young; 2015 Oct 23; 25(7):1311-8. PubMed ID: 25544036 [Abstract] [Full Text] [Related]
20. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin. Platt B, Belarski E, Manaloor J, Ofner S, Carroll AE, John CC, Wood JB. JAMA Netw Open; 2020 Jan 03; 3(1):e1918565. PubMed ID: 31899532 [Abstract] [Full Text] [Related] Page: [Next] [New Search]